2023-07-06 07:15:00
The bet for the vaccines continues to be a global priority and therefore should be so in the Ecuador, long-term.
Behind the health crisis due to covid-19, the immunization of adults and children became relevant. For this reason, it is expected that the next government will maintain this commitment, which seeks to cover the population against viruses.
For covid-19, now, there are the bivalent vaccines and, for the little ones, immunization, among others against measles, polio and rubella.
With the development of clinical studies and technological innovations in this field, it is expected that vaccines for the respiratory syncytial virus (VRS), citomegalovirus, metaneumovirusamong others.
In EU. It was announced that a dose of the vaccines will be available in the coming months. Pfizer (Abrysvo) and GSK (Arexvy) against RSV. These vaccines are for older than 60 years of age.
Last June, the Food and Drug Administration (FDA) approved these products.
Modern has also submitted applications for authorization to market its mRNA-1345 against RSV with the European Medicines Agency (EMA)), Swissmedicin Switzerland and the Therapeutic Goods Administration (TGA), in Australia. In addition, it began the process of submitting a biological license application to the FDA.
On the other hand, the UK Joint Committee on Vaccination and Immunization (JCVI) It has already recommended that the Government develop an immunization plan for RSV, which is cost-effective for babies and the elderly. These two age groups are the most vulnerable to this virus.
As the biotechnological innovations advances in the world, it is necessary that in Ecuador access to these vaccines be guaranteed in a timely, equitable and long-term manner.
More editorials:Visit our portals:
#commitment #vaccines #long #term